Phase 2 Trial Reports Positive Outcomes with Treatment Combination for Ovarian Cancer
The combination of pembrolizumab, bevacizumab and oral cyclophosphamide was well tolerated and demonstrated clinical benefit and durable treatment responses in patients with recurrent ovarian cancer.
Phase 2 non‑randomized clinical trial found that pembrolizumab, bevacizumab and oral cyclophosphamide were well tolerated and demonstrated clinical benefit and durable treatment responses in patients with recurrent ovarian cancer.
This combination offers a tolerable, effective strategy that extends disease control in recurrent ovarian cancer and may overcome the limited efficacy of checkpoint inhibitors alone.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Scientists discover why cancer drugs don’t work for everyone
- Epithelial ovarian cancer: prevention, diagnosis, and treatment
- Gynecologic Cancer InterGroup Consensus Recommendations on Clinical Research in Ovarian Cancer
- Why anti‑estrogen therapy fails in ovarian cancer, and how to make it work
- Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements